Overall survival advantage with partial nephrectomy: a bias of observational data?

Cancer. 2013 Aug 15;119(16):2981-9. doi: 10.1002/cncr.28141. Epub 2013 May 14.

Abstract

Background: Partial nephrectomy (PN) and radical nephrectomy (RN) are standard treatments for a small renal mass. Retrospective studies suggest an overall survival (OS) advantage, however a randomized phase 3 trial suggests otherwise. The effects of both surgical modalities on OS were evaluated compared with controls.

Methods: A matched cohort study was performed using the Surveillance, Epidemiology, and End Results (SEER)-Medicare dataset. Individuals treated with PN or RN for localized renal cell carcinoma (RCC) measuring ≤4 cm were compared with 2 control groups (non-muscle-invasive bladder cancer (BCC) and noncancer controls (NCC). Using a greedy algorithm, RCC groups were matched with controls by demographics and comorbidities. OS for surgical groups and controls were compared. The cause of death was evaluated for cancer groups when differences in OS were noted.

Results: Patients undergoing PN and RN were matched with controls. All cancer groups had >95% 10-year cancer-specific survival (CSS). Median OS was similar between RN (9.05 years) and BCC (8.67 years; P = .067) and NCC (8.77 years; P = .49). Median OS was improved for PN (10.45 years) compared with BCC (8.75 years; P<.001) and NCC controls (8.76 years; P<.001). A multivariate Cox hazards model demonstrated that PN improved OS compared with NCC (hazard ratio, 1.257; P<.001) and BCC (hazard ratio, 1.364; P<.001).

Conclusions: RN patients had similar OS compared with controls, suggesting that this treatment modality does not compromise survival. Patients undergoing PN had improved OS compared with controls, suggesting possible selection bias. The apparent survival advantage conferred by PN in SEER-Medicare case series is likely the result of selection bias involving unmeasured confounders.

Keywords: observational data; partial nephrectomy; radical nephrectomy; selection bias; survival advantage.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Aged
  • Carcinoma, Renal Cell / mortality*
  • Carcinoma, Renal Cell / surgery*
  • Clinical Trials, Phase III as Topic
  • Cohort Studies
  • Comorbidity
  • Female
  • Humans
  • Kidney Neoplasms / mortality*
  • Kidney Neoplasms / surgery*
  • Male
  • Nephrectomy / methods
  • Nephrectomy / mortality*
  • Randomized Controlled Trials as Topic
  • Retrospective Studies
  • SEER Program
  • Survival Analysis
  • Treatment Outcome
  • United States / epidemiology